TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Park Avenue Securities LLC

Park Avenue Securities LLC boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 3.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,797 shares of the company’s stock after purchasing an additional 322 shares during the quarter. Park Avenue Securities LLC’s holdings in TransMedics Group were worth $548,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TMDX. Driehaus Capital Management LLC lifted its holdings in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Geode Capital Management LLC increased its position in TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after buying an additional 10,106 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after buying an additional 30,092 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Canaccord Genuity Group decreased their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Finally, Robert W. Baird dropped their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Up 0.9 %

TransMedics Group stock opened at $62.55 on Friday. The stock’s 50 day moving average price is $69.56 and its 200 day moving average price is $115.95. The company has a market cap of $2.10 billion, a PE ratio of 66.54 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.